In contrast, MAO-B inhibitors may improve both depression and motivation symptoms, though the latter effect may be dependent on the severity of striatal dopaminergic neurodegeneration, potentially as a consequence of their mechanism of action depending on presynaptic dopaminergic neuron integrity. The gene discussed is MAOB; the disease is depressive symptom measurement.